Amanda L McGuire1, Christine F Carson1, Timothy J J Inglis2, Aron Chakera3. 1. Harry Perkins Institute of Medical Research, Nedlands, Western Australia School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia. 2. Department of Microbiology, PathWest Laboratory Medicine WA, Nedlands, Western Australia School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia. 3. Harry Perkins Institute of Medical Research, Nedlands, Western Australia School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia Renal Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia aron.chakera@uwa.edu.au.
Abstract
UNLABELLED: ♦ BACKGROUND: Peritonitis is a major complication of peritoneal dialysis (PD) and is associated with significant morbidity and mortality. Early empirical antibiotic therapy is recommended, with the choice of agents guided by local resistance patterns. As routine use of specific antimicrobial agents can drive resistance, regular assessment of causative organisms and their susceptibility to empirical therapy is essential. ♦ METHODS: We conducted a retrospective review of all PD peritonitis cases and positive PD fluid cultures obtained over a 5-year period in Western Australia following the introduction of a statewide protocol for the initial management of PD peritonitis with intraperitoneal vancomycin and gentamicin. ♦ RESULTS: The incidence of PD peritonitis decreased from 1 in 16 patient months (0.75/year at risk) to 1 in 29 patient months (0.41/year at risk) over the 5 years. There were 1,319 culture-positive samples and 1,069 unique isolates identified. Gram-positive bacteria accounted for 69.9% of positive cultures, with vancomycin resistance averaging 2% over the study period. Gram-negative bacteria accounted for 25.4% of positive cultures, with gentamicin resistance identified in an average of 8% of organisms. No increase in antimicrobial resistance to vancomycin or gentamicin occurred over the 5 years and there was no change in the proportion of gram-positive (69.9%), gram-negative (25.4%) or fungal (4.4%) organisms causing PD peritonitis. ♦ CONCLUSIONS: Over time, the peritonitis rates have dramatically improved although the profile of causative organisms remains similar. Empirical treatment of PD peritonitis with intraperitoneal vancomycin and gentamicin remains efficacious, with high levels of susceptibility and no evidence that the introduction of this statewide empirical PD peritonitis treatment protocol is driving resistance to these agents.
UNLABELLED: ♦ BACKGROUND: Peritonitis is a major complication of peritoneal dialysis (PD) and is associated with significant morbidity and mortality. Early empirical antibiotic therapy is recommended, with the choice of agents guided by local resistance patterns. As routine use of specific antimicrobial agents can drive resistance, regular assessment of causative organisms and their susceptibility to empirical therapy is essential. ♦ METHODS: We conducted a retrospective review of all PD peritonitis cases and positive PD fluid cultures obtained over a 5-year period in Western Australia following the introduction of a statewide protocol for the initial management of PD peritonitis with intraperitoneal vancomycin and gentamicin. ♦ RESULTS: The incidence of PD peritonitis decreased from 1 in 16 patient months (0.75/year at risk) to 1 in 29 patient months (0.41/year at risk) over the 5 years. There were 1,319 culture-positive samples and 1,069 unique isolates identified. Gram-positive bacteria accounted for 69.9% of positive cultures, with vancomycin resistance averaging 2% over the study period. Gram-negative bacteria accounted for 25.4% of positive cultures, with gentamicin resistance identified in an average of 8% of organisms. No increase in antimicrobial resistance to vancomycin or gentamicin occurred over the 5 years and there was no change in the proportion of gram-positive (69.9%), gram-negative (25.4%) or fungal (4.4%) organisms causing PD peritonitis. ♦ CONCLUSIONS: Over time, the peritonitis rates have dramatically improved although the profile of causative organisms remains similar. Empirical treatment of PD peritonitis with intraperitoneal vancomycin and gentamicin remains efficacious, with high levels of susceptibility and no evidence that the introduction of this statewide empirical PD peritonitis treatment protocol is driving resistance to these agents.
Authors: Jose Antonio Quintanar Lartundo; Rosa Palomar; Agustin Dominguez-Diez; Carlos Salas; Jorge Ruiz-Criado; Emilo Rodrigo; Angel Luis Martinez De Francisco; Manolo Arias Journal: Adv Perit Dial Date: 2011
Authors: Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk Journal: Perit Dial Int Date: 2010 Jul-Aug Impact factor: 1.756
Authors: Pasqual Barretti; Daniel Pereira; Maria Aparecida Brasil; Maria de Lourdes Cunha; Jacqueline Caramori; Augusto Montelli Journal: Perit Dial Int Date: 2009 Mar-Apr Impact factor: 1.756
Authors: Neil Boudville; Anna Kemp; Philip Clayton; Wai Lim; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Kathryn J Wiggins; Kym M Bannister; Fiona G Brown; David W Johnson Journal: J Am Soc Nephrol Date: 2012-05-24 Impact factor: 10.121
Authors: Joanna R Ghali; Kym M Bannister; Fiona G Brown; Johan B Rosman; Kathryn J Wiggins; David W Johnson; Stephen P McDonald Journal: Perit Dial Int Date: 2011-06-30 Impact factor: 1.756
Authors: Amanda L McGuire; Kieran T Mulroney; Christine F Carson; Ramesh Ram; Grant Morahan; Aron Chakera Journal: PLoS One Date: 2017-05-24 Impact factor: 3.240